[1] |
LU Yufeng, WANG Han, XIE Yifan, JIANG Yizhou, SHAO Zhimin.
Significant fundamental translational research on breast cancer in China: progress and prospects
[J]. China Oncology, 2025, 35(2): 143-153.
|
[2] |
FENG Xinying, WANG Bing, LIU Peifeng.
Innovations and challenges in intraperitoneal chemotherapy for peritoneal metastatic carcinoma
[J]. China Oncology, 2024, 34(9): 827-837.
|
[3] |
HUANG Haozhe, CHEN Hong, ZHENG Dezhong, CHEN Chao, WANG Ying, XU Lichao, WANG Yaohui, HE Xinhong, YANG Yuanyuan, LI Wentao.
A CT-based radiomics nomogram for predicting local tumor progression of colorectal cancer lung metastases treated with radiofrequency ablation
[J]. China Oncology, 2024, 34(9): 857-872.
|
[4] |
WU Wen, ZHANG Ruoxin, WENG Junyong, MA Yanlei, CAI Guoxiang, LI Xinxiang, YANG Yongzhi.
Exploring the prognostic value of positive lymph node ratio in stage Ⅲ colorectal cancer patients and establishing a predictive model
[J]. China Oncology, 2024, 34(9): 873-880.
|
[5] |
GE Zuyin, SONG Kun, LIN Yunxiao, ZHONG Yeling, HAO Jingduo.
The feasibility study of FCGBP and BIGH3 in circulating tumor cells as potential markers for colorectal cancer
[J]. China Oncology, 2024, 34(8): 745-752.
|
[6] |
CAO Xiaoshan, YANG Beibei, CONG Binbin, LIU Hong.
The progress of treatment for brain metastases of triple-negative breast cancer
[J]. China Oncology, 2024, 34(8): 777-784.
|
[7] |
LIAO Ziyi, PENG Yang, ZENG Beilei, MA Yingying, ZENG Li, GAN Kelun, MA Daiyuan.
Analysis of pathological remission degree and influencing factors of radical surgery after neoadjuvant immunotherapy combined with chemotherapy in patients with locally advanced esophageal squamous cell carcinoma
[J]. China Oncology, 2024, 34(7): 669-679.
|
[8] |
HUANG Sijie, KANG Xun, LI Wenbin.
Clinical research progress of intrathecal therapy in the treatment of leptomeningeal metastasis
[J]. China Oncology, 2024, 34(7): 695-701.
|
[9] |
WENG Junyong, YE Zilan, ZHANG Ruoxin, LIU Qi, LI Xinxiang.
Exploring the guiding role of the number of adverse pathological features in risk stratification for recurrence of stage Ⅰ-Ⅲ colorectal cancer: a retrospective cohort study of 9 875 cases
[J]. China Oncology, 2024, 34(6): 527-536.
|
[10] |
ZHANG Ruoxin, YE Zilan, WENG Junyong, LI Xinxiang.
Correlation study between advanced age and inferior prognosis in stage Ⅱ colorectal cancer patients
[J]. China Oncology, 2024, 34(5): 485-492.
|
[11] |
LU Yue, LU Renquan, ZHANG Jie, ZHENG Hui.
Application value of combined coagulation function indicators in monitoring hypercoagulable state of patients with colorectal cancer after chemotherapy
[J]. China Oncology, 2024, 34(3): 278-285.
|
[12] |
KE Zhui, GAO Jie, LU Jingyi, LUO Xinpei, HE Xuemin, LIU Zhuqing, YUAN Min, GUO Xianling, XU Qing.
A prospective single-arm study of the efficacy and safety of lobaplatin-based HIPEC combined with optimal support in the treatment of abdominal metastatic cancer
[J]. China Oncology, 2024, 34(12): 1115-1122.
|
[13] |
ZHAO Ting, ZHANG Xiaowei, LIU Xin, WANG Qifeng, HU Xichun, LUO Zhiguo.
Cancer of unknown primary: recent advancements in the diagnosis and treatment
[J]. China Oncology, 2024, 34(12): 1134-1143.
|
[14] |
FENG Huizhi, LIU Jingmei, BU Xiaoqian.
A retrospective study of pembrolizumab combined with XELOX regimen in the treatment of advanced gastric cancer
[J]. China Oncology, 2024, 34(11): 1028-1035.
|
[15] |
LI Jun, LU Tingwei, FANG Xuqian.
Impact of MSI-H/dMMR on clinicopathological characteristics and prognosis of patients with BRAF V600E-mutated resectable colorectal cancer
[J]. China Oncology, 2024, 34(11): 1061-1066.
|